Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zihua Wenfei Zhisou Granule is a Chinese herbal medicine formulation developed for the treatment of postinfectious cough, particularly in patients with wind-cold invading lungs syndrome. The granules are composed of multiple traditional Chinese medicinal herbs and are designed to relieve cough, wheezing, and reduce phlegm. Preclinical studies suggest that the formulation has antiallergic, anti-inflammatory, and antibacterial effects. Clinical trials have demonstrated its efficacy and safety in alleviating symptoms of postinfectious cough[1][2][3]. The product is manufactured by Yuekang Pharmaceutical (Beijing) and has been registered for clinical use in China. The precise mechanism of action is not fully elucidated due to the multi-component nature typical of traditional Chinese medicines; it exerts antitussive (cough-suppressing), anti-inflammatory, antiallergic, and antibacterial effects based on preclinical data[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zihua Wenfei Zhisou Granule.